Zocor vs. Praluent
See how Zocor and Praluent compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Zocor is a daily oral statin pill, while Praluent is an injectable PCSK9 inhibitor given every two or four weeks.
Praluent is typically added on top of statin therapy like Zocor when LDL remains too high, not used as a replacement for it.
Zocor has decades of use and low-cost generics, while Praluent is a newer biologic with no generic alternative and a much higher price.
Zocor vs. Praluent Drug Summary
Zocor
Zocor (simvastatin) is a statin that lowers LDL cholesterol by blocking a liver enzyme the body uses to make it. It is taken as a single oral tablet once a day, usually in the evening. It has been prescribed since 1991 and is now widely available as an inexpensive generic.
Praluent
Praluent (alirocumab) is a PCSK9 inhibitor, an injectable antibody that helps the liver clear more LDL cholesterol from the blood. It is self-injected under the skin every two weeks, or every four weeks at a higher dose. It is usually added to statin therapy when LDL is still too high.
Zocor vs. Praluent Side Effects
Zocor
Praluent
Zocor vs. Praluent Dosage
Zocor
Praluent
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg once daily | At the start |
| Maximum dose | 80 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 75 mg every 2 weeks | At the start |
| Maximum dose | 300 mg every 4 weeks | If needed |
| Dose changes | 2 increases | As tolerated |
Zocor
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg once daily | At the start |
| Maximum dose | 80 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Praluent
| STAGE | DOSE | WHEN |
| Starting dose | 75 mg every 2 weeks | At the start |
| Maximum dose | 300 mg every 4 weeks | If needed |
| Dose changes | 2 increases | As tolerated |
Zocor vs. Praluent Indications
Zocor
Zocor is FDA-approved to lower LDL cholesterol in adults with primary hyperlipidemia and to treat familial hypercholesterolemia, including in children 10 and older. It is also approved to reduce the risk of heart attack, stroke, and death in people with heart disease or diabetes at high cardiovascular risk.
Primary hyperlipidemia in adults
Heterozygous familial hypercholesterolemia (ages 10+)
Adjunct for homozygous familial hypercholesterolemia
Cardiovascular risk reduction in high-risk adults
Praluent
Praluent is FDA-approved to lower LDL cholesterol in adults with primary hyperlipidemia, usually added to diet and maximally tolerated statin therapy. It also treats heterozygous familial hypercholesterolemia in patients 8 and older and reduces the risk of heart attack, stroke, and hospitalization for unstable angina.
Primary hyperlipidemia, added to statin therapy
Heterozygous familial hypercholesterolemia (ages 8+)
Cardiovascular event risk reduction after heart disease
Not approved for homozygous familial hypercholesterolemia
Zocor vs. Praluent Pros and Cons
Zocor
Zocor is a well-established statin with decades of safety data and low-cost generic availability. As a pill taken once daily, it is simple to use, though it can interact with certain medications and carries a dose-related risk of muscle problems.
Pros
Inexpensive generic, roughly $75 to $100 per month
Taken as a simple oral tablet
Decades of real-world safety data since 1991
Approved as adjunct for homozygous familial hypercholesterolemia
Cons
Risk of myopathy and rhabdomyolysis, especially at 80 mg
Interacts with many drugs metabolized by CYP3A4
Contraindicated in pregnancy
Not approved for children under 10
Praluent
Praluent offers an option for patients who need more LDL lowering than a statin alone provides, using an antibody injection instead of a daily pill. It has strong outcomes data in patients with recent acute coronary syndrome, but it costs significantly more and has no generic alternative.
Pros
Effective add-on when statins alone aren't enough
Flexible dosing every 2 or 4 weeks
Approved for children as young as 8 with HeFH
Outcomes data from ODYSSEY OUTCOMES trial after acute coronary syndrome
Cons
Roughly $500 to $640 per month without insurance
Requires self-injection rather than a pill
No generic or biosimilar currently available
Not approved for homozygous familial hypercholesterolemia
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.